'Next-Gen' Immunotherapy Active in Advanced Cancers

(MedPage Today) -- An investigational drug that combines PD-1/L1 inhibition and T-cell stimulation led to disease control in two-thirds of patients with unresectable advanced solid malignancies, a preliminary clinical study showed.
Overall, 40...